Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo Stock Exchange  >  Sumitomo Dainippon Pharma Co., Ltd.    4506   JP3495000006

SUMITOMO DAINIPPON PHARMA CO., LTD.

(4506)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Tokyo Stock Exchange
11/26/2020 11/27/2020 11/30/2020 12/01/2020 12/02/2020 Date
1388 1386 1323 1314 1310 Last
1108500 878300 1449400 885500 1061700 Volume
+2.06% -0.14% -4.55% -0.68% -0.30% Change
Financials
Sales 2021 507 B 4 869 M 4 869 M
Net income 2021 21 341 M 205 M 205 M
Net Debt 2021 167 B 1 609 M 1 609 M
P/E ratio 2021 20,2x
Yield 2021 2,14%
Sales 2022 514 B 4 934 M 4 934 M
Net income 2022 29 727 M 286 M 286 M
Net Debt 2022 174 B 1 672 M 1 672 M
P/E ratio 2022 16,2x
Yield 2022 2,15%
Capitalization 526 B 5 031 M 5 053 M
EV / Sales 2021 1,37x
EV / Sales 2022 1,36x
Nbr of Employees 6 457
Free-Float 40,6%
More Financials
Company
Sumitomo Dainippon Pharma Co., Ltd. specializes in development, manufacturing and marketing of pharmaceutical products. Net sales break down by family of products as follows: - pharmaceutical products (92.3%): for cardiovascular, gastrointestinal and infectious diseases, central nervous systems disorders and allergies treatment; - other (7.7%): veterinary drugs, food additives, industrial chemical products,... 
Sector
Pharmaceuticals
Calendar
12/18Investor Meeting
More about the company
Notations Surperformance© of Sumitomo Dainippon Pharma Co., Ltd.
Trading Rating : Investor Rating :
More Ratings
All news about SUMITOMO DAINIPPON PHARMA CO., LTD.
11/26SUMITOMO DAINIPPON PHARMA : Urovant Sciences Announces Topline Data from Phase 2..
AQ
11/23Poxel Provides Update on Metavant Partnership with Imeglimin
AQ
11/16SUMITOMO DAINIPPON PHARMA : Sumitovant Enters into an Agreement for 'Going Priva..
AQ
11/13Myovant Sciences Announces Corporate Updates and Financial Results for Second..
AQ
10/29SUMITOMO DAINIPPON PHARMA : Announces Revisions to Its Financial Forecasts
AQ
10/29Japan stocks fall on coronavirus worries; upbeat earnings outlook limits loss..
RE
10/29SUMITOMO DAINIPPON PHARMA CO., LTD. : Press Release
CO
10/28Japanese shares touch one-month low on renewed coronavirus fears
RE
10/28Poxel Announces Participation at Several Upcoming Scientific and Investor Con..
AQ
10/28SUMITOMO DAINIPPON PHARMA CO., LTD. : Half-year results
CO
10/27SUMITOMO DAINIPPON PHARMA : Joint Research and Development Agreement with Drawbr..
AQ
10/21Poxel Provides Corporate Update and Reports Cash and Revenue for the Third Qu..
AQ
10/16Poxel Secures EUR 6 Million in Non-Dilutive Financing Guaranteed by the Frenc..
AQ
10/09SUMITOMO DAINIPPON PHARMA : Urovant Sciences Announces Co-Promotion Agreement fo..
AQ
09/29SUMITOMO DAINIPPON PHARMA CO., LTD. : Ex-dividend day for interim dividend
FA
More news
News in other languages on SUMITOMO DAINIPPON PHARMA CO., LTD.
09/16POXEL : A suivre aujourd'hui
09/15POXEL : 46 millions d'euros de trésorerie à la fin du premier semestre
05/08SUMITOMO DAINIPPON PHARMA CO., LTD. : Veröffentlichung des Jahresergebnisses
05/08SUMITOMO DAINIPPON PHARMA CO., LTD. : publication des résultats annuels
02/13CORRECTIF - POXEL : chiffre d'affaires 2019 en repli de 57%
More news
Chart SUMITOMO DAINIPPON PHARMA CO., LTD.
Duration : Period :
Sumitomo Dainippon Pharma Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SUMITOMO DAINIPPON PHARMA CO., LTD.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 9
Average target price 1 370,00 JPY
Last Close Price 1 310,00 JPY
Spread / Highest target 52,7%
Spread / Average Target 4,58%
Spread / Lowest Target -16,0%
EPS Revisions
Managers
NameTitle
Hiroshi Nomura President & Representative Director
Masayo Tada Chairman
Yoshiharu Ikeda GM-Production, Head-Research & Technology
Nobuhiko Tamura Director & Managing Executive Officer
Hitoshi Odagiri Director, GM-Sales & Head-Japan Business Unit
Sector and Competitors
1st jan.Capitalization (M$)
SUMITOMO DAINIPPON PHARMA CO., LTD.-38.50%4 978
JOHNSON & JOHNSON1.56%389 985
ROCHE HOLDING AG-3.61%289 019
PFIZER, INC.9.91%226 783
NOVARTIS AG-10.86%207 948
MERCK & CO., INC.-10.03%207 033